Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4565994 | 0.92 | KEAP1 (0.38) | KEAP1NFE2L2 | |
| SCHEMBL13390781 | 0.91 | GPR119 (0.38) | KEAP1NFE2L2 | |
| SCHEMBL3297170 | 0.90 | KEAP1 (0.36) | KEAP1NFE2L2 | |
| SCHEMBL4439278 | 0.87 | KEAP1 (0.36) | KEAP1NFE2L2 | |
| SCHEMBL3301080 | 0.86 | KEAP1 (0.32) | KEAP1NFE2L2 | |
| SCHEMBL4432779 | 0.85 | KEAP1 (0.35) | KEAP1NFE2L2 | |
| SCHEMBL3299982 | 0.83 | ROCK1 (0.33) | KEAP1NFE2L2 | |
| SCHEMBL3301072 | 0.83 | KEAP1 (0.39) | KEAP1NFE2L2 | |
| SCHEMBL13391403 | 0.83 | KEAP1 (0.35) | KEAP1NFE2L2 | |
| Hydrochloric Acid SCHEMBL3298188 | 0.82 | KEAP1 (0.34) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121600-B1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-18 | — | — | EP | disclosed |
| EP-2121600-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | Boehringer Ingelheim International GmbH (DE) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099000-A2 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-21 | — | — | WO | disclosed |